Transparency Market Research
Ulcerative Colitis Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
Single User License: USD 4315.5
Transparency Market Research State Tower, 90, State Street, Suite 700. Albany, NY 12207 United States www.transparencymarketresearch.com sales@transparencymarketresearch.co m
Flat 10% Discount!! Free Customization as per your requirement You will get Custom Report at Syndicated Report price Report will be delivered with in 15-20 working days
Request Sample
Buy Now
REPORT DESCRIPTION
Transparency Market Research Reports incorporated a definite business overview and investigation inclines on "Ulcerative Colitis Therapeutics Market". This report likewise incorporates more illumination about fundamental review of the business including definitions, requisitions and worldwide business sector industry structure. Ulcerative colitis is a chronic idiopathic inflammatory bowel disease (IBD) of the gastrointestinal tract that affects the mucosal lining of the colon commonly occur in people aged between 15-30 years. Ulcerative colitis is one of the 2 major types of IBD along with Crohn’s disease. Unlike Crohn’s disease, which can affect any part of the gastrointestinal tract, ulcerative colitis characteristically involves only the large bowel. The actual cause of the disease is still unidentified but with the available information it may be the result of an over reactive immune response to normal bacteria and other substances in the gastrointestinal tract.The prominent symptoms of ulcerative colitis are abdominal pain and bloody diarrhea due to inflammation and the development of open sores (ulcers) in the large intestine (colon) and rectum. Other symptoms of ulcerative colitis include abdominal cramping, nausea, fever, skin ulcers, loss of appetite, weight loss, joint pain, and fatigue. Severe complications of ulcerative colitis include hemorrhage, colon rupture, and the possible development of colon cancer. About 20% of people with ulcerative colitis have a family member with the disease or with Crohn\'s disease which is also a type of IBD. There is no known cure for ulcerative colitis till now, but therapies are available that may significantly reduce the signs and symptoms of ulcerative colitis and even bring about a long-term remission. Browse Full Report with TOC: http://www.transparencymarketresearch.com/ulcerative-colitis-therapeutics-market.html The report starts by providing the definition and symptoms of ulcerative colitis. Ulcerative colitis is a type of inflammatory bowel disease causing ulcers and inflammation in the colon, the biggest part of the large intestine, either partially or completely. The prime symptom of an active disease includes diarrhea and blood. This disease can sometimes result in life-threatening complications owing to the fact that it is a result of the abnormal response of the immune system. It is primarily prevalent in the age group ranging from 15 to 30 years. As per the report, at present there is no known cure for this disease; however, the launch of new therapeutics may offer symptomatic treatment options.
In terms of drug class, the report segments the market for ulcerative colitis therapeutics into aminosalicylates, corticosteroids, immune modulators, antibiotics, and others. The segment of aminosalicylates is further segmented into sulfasalazine, balsalazide, and mesalamine. The segment of corticosteroids is further segmented into prednisone and methylprednisolone while the segment of antibiotics is further segmented into ciprofloxacin and ampicillin. Factors such as the high sales of the already existing drugs and the strong pipeline of therapeutic products will stimulate the growth of the market. Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php? flag=B&rep_id=2185 The report states that some of the recently launched FDA-approved drugs for the treatment of ulcerative colitis include SIMPONI ARIA, an infusion treatment by Janssen Biotech, Inc. This drug was launched in July 2013. Santarus Inc. launched UCERIS in January 2013 while Warner Chilcott introduced DELZICOL in April 2013. In terms of geography, the report segments the market into Asia Pacific, North America, Europe, and Rest of the World (RoW). North America, Northern Europe, and the UK have reported the highest ulcerative colitis cases in the past few years, as per the U.S Pharmacist. As stated in the report, the key manufacturers operating in the market are Johnson & Johnson, Takeda Pharmaceutical Company, Janssen Biotech, Inc., Abbott Laboratories, and Pfizer Inc., among others. This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include •
North America
•
Asia Pacific
•
Europe
•
Rest of the World
This report provides comprehensive analysis of
•
Market growth drivers
•
Factors limiting market growth
•
Current market trends
•
Market structure
•
Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.
About Us Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Contact: Transparency Market Research 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com/